Vaxart 提供代理投票的最新更新，並敦促截至 2022 年 4 月 11 日記錄的所有股東在 2022 年 8 月 3 日下午 11:59 （美國東部時間）前投票。
27 juil. 2022 15h28 HE
|
Vaxart, Inc.
關鍵提案 #2 需要額外 0.9% 的流通股投票才能通過 領先的獨立代理諮詢公司 ISS 和 Glass Lewis 支持提案 #2 加利福尼亞州南舊金山, July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) 今天敦促其截至 2022 年 4 月 11...
Vaxart ofrece una nueva actualización sobre el voto por delegación e insta a todos los accionistas registrados a fecha del 11 de abril de 2022 a votar antes del 3 de agosto de 2022, a las 11:59 p. m. ET.
27 juil. 2022 15h28 HE
|
Vaxart, Inc.
La Propuesta Clave n.º 2 necesita un 0,9 % adicional de votos de las acciones en circulación para su aprobación Las Firmas Asesoras Independientes destacadas, ISS y Glass Lewis, apoyan la Propuesta...
Vaxart fornisce un nuovo aggiornamento sul voto per delega e invita tutti gli azionisti registrati all’11 aprile 2022 a votare entro il 3 agosto 2022, alle 23:59 ET
27 juil. 2022 15h28 HE
|
Vaxart, Inc.
La proposta chiave n. 2 necessita di un ulteriore 0,9% di voti delle azioni in circolazione per essere approvata Le principali società di consulenza indipendente, ISS e Glass Lewis, sostengono la...
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
27 juil. 2022 08h00 HE
|
Vaxart, Inc.
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., July 27,...
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
20 juil. 2022 08h30 HE
|
Vaxart, Inc.
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it...
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
14 juil. 2022 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior...
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
01 juil. 2022 09h00 HE
|
Vaxart, Inc.
Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO,...
Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model
30 juin 2022 08h00 HE
|
Vaxart, Inc.
Model will be used in Vaxart’s Phase II Omicron Challenge Trial Open Orphan subsidiary hVIVO to manufacture challenge virus and conduct characterization study SOUTH SAN FRANCISCO, Calif.,...
Vaxart to Host Investor Q&A Webcast
16 juin 2022 16h05 HE
|
Vaxart, Inc.
Management to discuss progress on its programs, annual stockholders’ meeting proposals Webcast to be held on June 22 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) --...
Vaxart Announces Adjournment of Annual Meeting of Stockholders
08 juin 2022 09h05 HE
|
Vaxart, Inc.
Meeting adjourned to July 6, 2022 at 9:30 a.m. PT Vaxart encourages all stockholders of record on April 11, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on July 5, 2022 SOUTH SAN...